Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia

Leukemia

Volumn 26, Issue 6, 2012, Pages 1228-1237

  Hofmann, M ^a   Grobe Hovest, L ^a   Nubling T ^a   Pyz, E ^a   Bamberg, M L ^a   Aulwurm, S ^a   Buhring H J ^a   Schwartz, K ^a   Haen, S P ^a   Schilbach, K ^a   Rammensee, H G ^a   Salih, H R ^a   Jung, G ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

ADCC; AML; FLT3; optimized antibody; tumor immunotherapy

Indexed keywords

CD135 ANTIGEN; FC RECEPTOR; FLT3 LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4G8SDIEM; MONOCLONAL ANTIBODY BV10SDIEM; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG TARGETING; GENE MUTATION; GLYCOSYLATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIGAND BINDING; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BLAST CRISIS; CELLS, CULTURED; DENDRITIC CELLS; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID; MICE; RECEPTORS, FC;

EID: 84862020736     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.372     Document Type: Article

References (35)

1. Oflazoglu E, Audoly LP. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2010; 2: 14-19.
2. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10: 345-352.
3. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278: 3466-3473. (Pubitemid 36801263)
4. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103: 4005-4010.
5. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009; 10: 588-596.
6. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson Jr DM et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010; 115: 1204-1213.
7. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008; 68: 8049-8057.
8. Foyil KV, Bartlett NL. Anti-CD30 antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep 2010; 5: 140-147.
9. Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005; 23: 4110-4116. (Pubitemid 46211316)
10. Roberts AW, He S, Ritchie D, Hertzberg MS, Kerridge I, Durrant ST et al. A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML. J Clin Oncol (Meet Abstr) 2010; 28 (15-Suppl): e13012.
11. Kikushige Y, Yoshimoto G, Miyamoto T, Iino T, Mori Y, Iwasaki H et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol 2008; 180: 7358-7367.
12. Dahl C, Hoffmann HJ, Saito H, Schiotz PO. Human mast cells express receptors for IL-3, IL-5 and GM-CSF; a partial map of receptors on human mast cells cultured in vitro. Allergy 2004; 59: 1087-1096. (Pubitemid 39279107)
13. Toba K, Koike T, Shibata A, Hashimoto S, Takahashi M, Masuko M et al. Novel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophils. Cytometry 1999; 35: 249-259. (Pubitemid 29104403)
14. Lim LH, Burdick MM, Hudson SA, Mustafa FB, Konstantopoulos K, Bochner BS. Stimulation of human endothelium with IL-3 induces selective basophil accumulation in vitro. J Immunol 2006; 176: 5346-5353.
15. Rappold I, Ziegler BL, Kohler I, Marchetto S, Rosnet O, Birnbaum D et al. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood 1997; 90: 111-125. (Pubitemid 27276554)
16. Meeker TC, Miller RA, Link MP, Bindl J, Warnke R, Levy R. A unique human B lymphocyte antigen defined by a monoclonal antibody. Hybridoma 1984; 3: 305-320. (Pubitemid 15126236)
17. Weisberg E, Sattler M, Ray A, Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene 2010; 29: 5120-5134.
18. Dong J, McPherson CM, Stambrook PJ. Flt-3 ligand: a potent dendritic cell stimulator and novel antitumor agent. Cancer Biol Ther 2002; 1: 486-489.
19. McKenna HJ. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells. Curr Opin Hematol 2001; 8: 149-154. (Pubitemid 32324635)
20. Waskow C, Liu K, Darrasse-Jeze G, Guermonprez P, Ginhoux F, Merad M et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol 2008; 9: 676-683. (Pubitemid 351712638)
21. Harada S, Kimura T, Fujiki H, Nakagawa H, Ueda Y, Itoh T et al. Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: possible application for cancer immunotherapy. Int J Oncol 2007; 30: 1461-1468.
22. Kingston D, Schmid MA, Onai N, Obata-Onai A, Baumjohann D, Manz MG. The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. Blood 2009; 114: 835-843.
23. Herrmann T, Grosse-Hovest L, Otz T, Krammer PH, Rammensee HG, Jung G. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008; 68: 1221-1227. (Pubitemid 351272242)
24. Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol 2003; 33: 1334-1340. (Pubitemid 36609151)
25. Evan GI, Lewis GK, Ramsay G, Bishop JM. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 1985; 5: 3610-3616. (Pubitemid 16233068)
26. Jung G, Freimann U, Von MZ, Reisfeld RA, Wilmanns W. Target cell-induced T cell activation with bi-and trispecific antibody fragments. Eur J Immunol 1991; 21: 2431-2435.
27. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
28. Otz T, Grosse-Hovest L, Hofmann M, Rammensee HG, Jung G. A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells. Leukemia 2009; 23: 71-77.
29. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-212.
30. Sanz M, Burnett A, Lo-Coco F, Lowenberg B. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr Opin Oncol 2009; 21: 594-600.
31. Piloto O, Levis M, Huso D, Li Y, Li H, Wang MN et al. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2005; 65: 1514-1522. (Pubitemid 40276832)
32. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998; 51: 364-369. (Pubitemid 28289122)
33. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010; 115: 5191-5201.
34. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176: 2600-2609. (Pubitemid 43201712)
35. Davis ID, Chen Q, Morris L, Quirk J, Stanley M, Tavarnesi ML et al. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother 2006; 29: 499-511. (Pubitemid 44395275)